| 155.96 0.05 (0.03%) | 04-24 15:47 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Hill-Rom Holdings, Inc. functions as a global enterprise specializing in medical technology, structured into three primary operational areas: Patient Support Systems, Front Line Care, and Surgical Solutions. The Patient Support Systems division provides a variety of essential equipment, including medical-surgical, intensive care unit, and bariatric patient beds, alongside patient lifts and related devices, non-invasive therapeutic surfaces, and cutting-edge information technology and software. This segment also offers service contracts for its capital equipment. Under its Front Line Care offerings, the company furnishes comprehensive patient monitoring and diagnostic instruments. These encompass general patient examination and diagnostic tools, continuous patient monitoring systems, diagnostic cardiology products, and vision screening devices. Additionally, it supplies a suite of respiratory health products, such as the Vest System, VitalCough System, MetaNeb System, Monarch, and Life2000, all designed to facilitate the mobilization of retained blockages in patients. The Surgical Solutions segment delivers critical operating room infrastructure, including surgical tables, specialized lighting, and ceiling-mounted pendants. It also manufactures precision positioning devices for various procedures like shoulder, hip, spinal, and lithotomy surgeries, along with universal positioning accessories compatible with diverse operating room tables. Hill-Rom's products and services reach a broad spectrum of healthcare providers. They are distributed and leased directly to acute and extended care facilities through its dedicated sales force and various distributors. The company also sells and rents directly to individual patients for home use and supplies primary care facilities via distribution partners. Its comprehensive clinical offerings cater to acute care, primary care, and even clinical research organizations. Established in 1969, Hill-Rom Holdings, Inc. maintains its headquarters in Chicago, Illinois.
Sat, 14 Dec 2024
Hill-Rom Holdings (NYSE:HRC) - intelligentinvestor.com.au
Thu, 06 Apr 2023
Daniel A Hillenbrand Net Worth (2026) - GuruFocus
Thu, 02 Sep 2021
Medtech firm Baxter to buy hospital-bed maker Hill-Rom for $10.5 bln - Reuters
Tue, 01 Dec 2020
Hill-rom Holdings Stock Price Forecast. Should You Buy HRC? - StockInvest.us
Wed, 10 Jul 2019
Hillrom Announces Sale Of Surgical Consumable Products - PR Newswire
Tue, 28 May 2019
Hill-Rom Unveils New Corporate Logo And Global Brand Identity - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|